Noppacharn Uaprasert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Noppacharn Uaprasert has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Ponlapat Rojnuckarin
Division of Hematology, Department of Medicine, Faculty of Medicine , Chulalongkorn University and King Chulalongkorn Memorial Hospital , Bangkok, Thailand
12 shared publications- Ponlapat Rojnuckarin
Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
12 shared publications Pranee Sutcharitchan
Division of Hematology, Department of Internal Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok Thailand
8 shared publicationsBenjaporn Akkawat
Department of Medicine Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok Thailand
6 shared publications- Chatphatai Moonla
Division of General Internal Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
5 shared publications Rung Settapiboon
Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand
5 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Challenges in venous thromboembolism prophylaxis: a narrative review of East and Southeast Asian perspectives
- 12 June 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Open AccessChallenges in venous thromboembolism prophylaxis: a narrative review of East and Southeast Asian perspectives
- Open Access
- 14 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40020
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial
The role of antibacterial prophylaxis in non-Hodgkin lymphoma (NHL) patients undergoing Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisolone (R-CHOP) chemotherapy with granulocyte-colony stimulating factor (G-CSF) support remains uncertain. This study evaluates the efficacy of levofloxacin in preventing febrile episodes in these patients. A randomized, single-blind, placebo-controlled trial was conducted, enrolling NHL patients receiving R-CHOP every 21-day cycle between January 2023 and June 2024. Patients were randomized to receive levofloxacin 500 mg once daily or placebo from day 1 to day 7 post-chemotherapy. All patients received G-CSF support. The primary outcome was the occurrence of febrile episodes within 120 days. Eighty participants were equally randomized into two groups. The median age was 64 years. In the intention-to-treat analysis, the first febrile episode was documented in 3 (7.5%) and 12 (30%) participants in the levofloxacin and placebo groups, respectively (P = 0.010). Levofloxacin prophylaxis significantly reduced febrile neutropenia (2.5% vs. 20%, P = 0.029) and the composite of febrile episodes, septic shock, all-cause mortality and chemotherapy dose reduction (10% vs. 30%, P = 0.025). The hazard ratio (HR) for fever-free survival with levofloxacin prophylaxis was 0.23 (95% CI 0.06–0.80; P = 0.012). Multivariate analysis showed levofloxacin was associated with a lower risk of febrile episodes (adjusted HR 0.17, 95% CI, 0.05–0.66; P = 0.01). No differences in mortality or serious adverse events were observed. Levofloxacin prophylaxis is an effective, well-tolerated strategy to reduce febrile episodes, febrile neutropenia and composite adverse outcomes after R-CHOP chemotherapy, despite concurrent G-CSF support. Long-term antibiotic resistance monitoring is warranted. Trial registration: This trial is registered at Thai Clinical Trials Registry (TCTR), number TCTR20230719005.
- 14 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40020
Open AccessLevofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial
The role of antibacterial prophylaxis in non-Hodgkin lymphoma (NHL) patients undergoing Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisolone (R-CHOP) chemotherapy with granulocyte-colony stimulating factor (G-CSF) support remains uncertain. This study evaluates the efficacy of levofloxacin in preventing febrile episodes in these patients. A randomized, single-blind, placebo-controlled trial was conducted, enrolling NHL patients receiving R-CHOP every 21-day cycle between January 2023 and June 2024. Patients were randomized to receive levofloxacin 500 mg once daily or placebo from day 1 to day 7 post-chemotherapy. All patients received G-CSF support. The primary outcome was the occurrence of febrile episodes within 120 days. Eighty participants were equally randomized into two groups. The median age was 64 years. In the intention-to-treat analysis, the first febrile episode was documented in 3 (7.5%) and 12 (30%) participants in the levofloxacin and placebo groups, respectively (P = 0.010). Levofloxacin prophylaxis significantly reduced febrile neutropenia (2.5% vs. 20%, P = 0.029) and the composite of febrile episodes, septic shock, all-cause mortality and chemotherapy dose reduction (10% vs. 30%, P = 0.025). The hazard ratio (HR) for fever-free survival with levofloxacin prophylaxis was 0.23 (95% CI 0.06–0.80; P = 0.012). Multivariate analysis showed levofloxacin was associated with a lower risk of febrile episodes (adjusted HR 0.17, 95% CI, 0.05–0.66; P = 0.01). No differences in mortality or serious adverse events were observed. Levofloxacin prophylaxis is an effective, well-tolerated strategy to reduce febrile episodes, febrile neutropenia and composite adverse outcomes after R-CHOP chemotherapy, despite concurrent G-CSF support. Long-term antibiotic resistance monitoring is warranted. Trial registration: This trial is registered at Thai Clinical Trials Registry (TCTR), number TCTR20230719005.
- Open Access
- 1 August 2025
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 19 (4) , 165-173
Effects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen
Background: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in diffuse large B-cell lymphoma (DLBCL) patients undergoing rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone every 21 d (R-CHOP-21) chemotherapy varies based on physician discretion. Objectives: The present study aims to investigate the impact of primary G-CSF prophylaxis on febrile neutropenia (FN) and other outcomes in DLBCL patients receiving R-CHOP-21 in real-world practice. Methods: Medical records of 103 newly diagnosed DLBCL patients, aged 18–80 years, were retrospectively analyzed. Seventy-four patients received primary G-CSF prophylaxis (prophylaxis group), while 29 patients did not receive prophylaxis (non-prophylaxis group). The occurrence of FN and other outcomes was compared between the two groups. Results: The prophylaxis group had older patients (median ± interquartile ranges [IQR], 63 ± 12 years vs. 50 ± 15 years, P < 0.001). The incidence of FN after the first R-CHOP was not statistically significant between groups (8.3% vs. 17.2%, P = 0.177). However, FN events were significantly higher in non-prophylaxis cycles (7.40%) compared with prophylaxis cycles (2.70%) ( P = 0.027). Cumulative FN events were lower in the prophylaxis group (14.9%) than in the non-prophylaxis group (27.6%) ( P = 0.134). FN-free survival was not significantly different between prophylaxis and non-prophylaxis groups (hazard ratio [HR], 0.48; 95% confidence interval [95%CI], 0.17–1.35), while primary G-CSF prophylaxis significantly improved event-free survival (HR, 0.36; 95%CI, 0.16–0.84). Conclusions: Primary G-CSF prophylaxis may reduce the risk of FN in DLBCL patients undergoing R-CHOP-21 treatment. The present study highlights the importance of primary G-CSF prophylaxis, especially for those at high risk of FN.
- 1 August 2025
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 19 (4) , 165-173
Open AccessEffects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen
Background: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in diffuse large B-cell lymphoma (DLBCL) patients undergoing rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone every 21 d (R-CHOP-21) chemotherapy varies based on physician discretion. Objectives: The present study aims to investigate the impact of primary G-CSF prophylaxis on febrile neutropenia (FN) and other outcomes in DLBCL patients receiving R-CHOP-21 in real-world practice. Methods: Medical records of 103 newly diagnosed DLBCL patients, aged 18–80 years, were retrospectively analyzed. Seventy-four patients received primary G-CSF prophylaxis (prophylaxis group), while 29 patients did not receive prophylaxis (non-prophylaxis group). The occurrence of FN and other outcomes was compared between the two groups. Results: The prophylaxis group had older patients (median ± interquartile ranges [IQR], 63 ± 12 years vs. 50 ± 15 years, P < 0.001). The incidence of FN after the first R-CHOP was not statistically significant between groups (8.3% vs. 17.2%, P = 0.177). However, FN events were significantly higher in non-prophylaxis cycles (7.40%) compared with prophylaxis cycles (2.70%) ( P = 0.027). Cumulative FN events were lower in the prophylaxis group (14.9%) than in the non-prophylaxis group (27.6%) ( P = 0.134). FN-free survival was not significantly different between prophylaxis and non-prophylaxis groups (hazard ratio [HR], 0.48; 95% confidence interval [95%CI], 0.17–1.35), while primary G-CSF prophylaxis significantly improved event-free survival (HR, 0.36; 95%CI, 0.16–0.84). Conclusions: Primary G-CSF prophylaxis may reduce the risk of FN in DLBCL patients undergoing R-CHOP-21 treatment. The present study highlights the importance of primary G-CSF prophylaxis, especially for those at high risk of FN.
- Open Access
- 1 January 2025
- Published by Allergy, Asthma, and Immunology Association of Thailand in Asian Pacific Journal of Allergy and Immunology
- Vol. 43 (3) , 586-589
Thrombosis with thrombocytopenia after the second ChAdOx1 nCoV-19 vaccination: A possible immunological mechanism independent of anti-platelet factor 4 antibody
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a distinctive syndrome characterized by unusual site thrombosis accompanied by thrombocytopenia following adenoviral vector vaccines against severe acute respiratory syndrome coronavirus 2. Platelet-activating anti-platelet factor 4-dependent antibodies (anti-PF4 Abs) have been identified as pathogenic antibodies in almost all patients. We proposed an immunological mechanism of VITT independent of anti-PF4 Abs. Case report. A 68-year-old Thai woman developed pulmonary embolism and deep vein thrombosis with thrombocytopenia one week after the second ChAdOx1 nCoV-19 vaccination with undetectable anti-PF4 Abs. The platelet count responded rapidly to intravenous immunoglobulin and steroids. Therefore, the high clinical suspicion is essential for early recognition and prompt management irrespective of anti-PF4 Ab results. We hypothesize that platelet and endothelial activation following ChAdOx1 nCoV-19 vaccination may lead to generation of pathogenic antibodies which account for VITT independent of anti-PF4 Abs.
- 1 January 2025
- Published by Allergy, Asthma, and Immunology Association of Thailand in Asian Pacific Journal of Allergy and Immunology
- Vol. 43 (3) , 586-589
Open AccessThrombosis with thrombocytopenia after the second ChAdOx1 nCoV-19 vaccination: A possible immunological mechanism independent of anti-platelet factor 4 antibody
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a distinctive syndrome characterized by unusual site thrombosis accompanied by thrombocytopenia following adenoviral vector vaccines against severe acute respiratory syndrome coronavirus 2. Platelet-activating anti-platelet factor 4-dependent antibodies (anti-PF4 Abs) have been identified as pathogenic antibodies in almost all patients. We proposed an immunological mechanism of VITT independent of anti-PF4 Abs. Case report. A 68-year-old Thai woman developed pulmonary embolism and deep vein thrombosis with thrombocytopenia one week after the second ChAdOx1 nCoV-19 vaccination with undetectable anti-PF4 Abs. The platelet count responded rapidly to intravenous immunoglobulin and steroids. Therefore, the high clinical suspicion is essential for early recognition and prompt management irrespective of anti-PF4 Ab results. We hypothesize that platelet and endothelial activation following ChAdOx1 nCoV-19 vaccination may lead to generation of pathogenic antibodies which account for VITT independent of anti-PF4 Abs.
- 30 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (2) , 703-712
Impact of HbE mutation on the clinical severity of HbH disease: A multicentre study from Thailand
Summary: Haemoglobin (Hb) H disease and HbH disease with co‐inherited HbE mutation are the most prevalent forms of α‐thalassaemia in Southeast Asia. Data were limited when comparing clinical phenotypes between these two patient groups. We conducted a Thai multicentre study and enrolled 588 patients [median (IQR) age 13.0 (6.7–20.3) years], including those with deletional HbH disease with (n = 47) and without (n = 187) co‐inherited HbE mutation and non‐deletional HbH disease with (n = 101) and without (n = 253) co‐inherited HbE mutation. Patients with HbH disease with co‐inherited HbE mutation suffered more severe manifestations than those without. This observation was more pronounced in patients with non‐deletional HbH disease. A greater proportion of patients with non‐deletional HbH disease with co‐inherited HbE mutation (43.6%) eventually required regular transfusions compared to those without (30.4%, p = 0.019). Among those with non‐deletional HbH disease who did not require regular transfusions, Hb levels were lower in patients with co‐inherited HbE mutation [8.1 (7.2–8.6) vs. 8.8 (8.2–9.5) g/dL, p < 0.001]. Among patients requiring regular transfusions who underwent splenectomy, 11/12 patients with non‐deletional HbH disease stopped transfusion compared with 1/3 in non‐deletional HbH disease with co‐inherited HbE mutation group (p = 0.024). These findings provide insights for the clinical monitoring and management of HbH disease in the region.
- 30 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (2) , 703-712
Impact of HbE mutation on the clinical severity of HbH disease: A multicentre study from Thailand
Summary: Haemoglobin (Hb) H disease and HbH disease with co‐inherited HbE mutation are the most prevalent forms of α‐thalassaemia in Southeast Asia. Data were limited when comparing clinical phenotypes between these two patient groups. We conducted a Thai multicentre study and enrolled 588 patients [median (IQR) age 13.0 (6.7–20.3) years], including those with deletional HbH disease with (n = 47) and without (n = 187) co‐inherited HbE mutation and non‐deletional HbH disease with (n = 101) and without (n = 253) co‐inherited HbE mutation. Patients with HbH disease with co‐inherited HbE mutation suffered more severe manifestations than those without. This observation was more pronounced in patients with non‐deletional HbH disease. A greater proportion of patients with non‐deletional HbH disease with co‐inherited HbE mutation (43.6%) eventually required regular transfusions compared to those without (30.4%, p = 0.019). Among those with non‐deletional HbH disease who did not require regular transfusions, Hb levels were lower in patients with co‐inherited HbE mutation [8.1 (7.2–8.6) vs. 8.8 (8.2–9.5) g/dL, p < 0.001]. Among patients requiring regular transfusions who underwent splenectomy, 11/12 patients with non‐deletional HbH disease stopped transfusion compared with 1/3 in non‐deletional HbH disease with co‐inherited HbE mutation group (p = 0.024). These findings provide insights for the clinical monitoring and management of HbH disease in the region.
- Open Access
- 4 November 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (1) , 290-295
Severe iron overload cardiomyopathy manifested as acute myopericarditis: A case report
- 4 November 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (1) , 290-295
Open AccessSevere iron overload cardiomyopathy manifested as acute myopericarditis: A case report
- 4 September 2023
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1649-1652
Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers
- 4 September 2023
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1649-1652
Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers
- Open Access
- 23 December 2022
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12 (12) , 1-13
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Patients with hematologic malignancies (HM) have demonstrated impaired immune responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity remain largely undetermined. A literature search was conducted using PubMed, EMBASE, Cochrane, and medRxiv databases to identify studies that reported humoral or cellular immune responses (CIR) following complete SARS-CoV-2 vaccination. The primary aim was to estimate the seroconversion rate (SR) following complete SARS-CoV-2 vaccination across various subtypes of HM diseases and treatments. The secondary aims were to determine the rates of development of neutralizing antibodies (NAb) and CIR following complete vaccination and SR following booster doses. A total of 170 studies were included for qualitative and quantitative analysis of primary and secondary outcomes. A meta-analysis of 150 studies including 20,922 HM patients revealed a pooled SR following SARS-CoV-2 vaccination of 67.7% (95% confidence interval [CI], 64.8–70.4%; I2 = 94%). Meta-regression analysis showed that patients with lymphoid malignancies, but not myeloid malignancies, had lower seroconversion rates than those with solid cancers (R2 = 0.52, P < 0.0001). Patients receiving chimeric antigen receptor T-cells (CART), B-cell targeted therapies or JAK inhibitors were associated with poor seroconversion (R2 = 0.39, P < 0.0001). The pooled NAb and CIR rates were 52.8% (95% CI; 45.8–59.7%, I2 = 87%) and 66.6% (95% CI, 57.1–74.9%; I2 = 86%), respectively. Approximately 20.9% (95% CI, 11.4–35.1%, I2 = 90%) of HM patients failed to elicit humoral and cellular immunity. Among non-seroconverted patients after primary vaccination, only 40.5% (95% CI, 33.0–48.4%; I2 = 87%) mounted seroconversion after the booster. In conclusion, HM patients, especially those with lymphoid malignancies and/or receiving CART, B-cell targeted therapies, or JAK inhibitors, showed poor SR after SARS-CoV-2 vaccination. A minority of patients attained seroconversion after booster vaccination. Strategies to improve immune response in these severely immunosuppressed patients are needed.
- 23 December 2022
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12 (12) , 1-13
Open AccessImmunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Patients with hematologic malignancies (HM) have demonstrated impaired immune responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity remain largely undetermined. A literature search was conducted using PubMed, EMBASE, Cochrane, and medRxiv databases to identify studies that reported humoral or cellular immune responses (CIR) following complete SARS-CoV-2 vaccination. The primary aim was to estimate the seroconversion rate (SR) following complete SARS-CoV-2 vaccination across various subtypes of HM diseases and treatments. The secondary aims were to determine the rates of development of neutralizing antibodies (NAb) and CIR following complete vaccination and SR following booster doses. A total of 170 studies were included for qualitative and quantitative analysis of primary and secondary outcomes. A meta-analysis of 150 studies including 20,922 HM patients revealed a pooled SR following SARS-CoV-2 vaccination of 67.7% (95% confidence interval [CI], 64.8–70.4%; I2 = 94%). Meta-regression analysis showed that patients with lymphoid malignancies, but not myeloid malignancies, had lower seroconversion rates than those with solid cancers (R2 = 0.52, P < 0.0001). Patients receiving chimeric antigen receptor T-cells (CART), B-cell targeted therapies or JAK inhibitors were associated with poor seroconversion (R2 = 0.39, P < 0.0001). The pooled NAb and CIR rates were 52.8% (95% CI; 45.8–59.7%, I2 = 87%) and 66.6% (95% CI, 57.1–74.9%; I2 = 86%), respectively. Approximately 20.9% (95% CI, 11.4–35.1%, I2 = 90%) of HM patients failed to elicit humoral and cellular immunity. Among non-seroconverted patients after primary vaccination, only 40.5% (95% CI, 33.0–48.4%; I2 = 87%) mounted seroconversion after the booster. In conclusion, HM patients, especially those with lymphoid malignancies and/or receiving CART, B-cell targeted therapies, or JAK inhibitors, showed poor SR after SARS-CoV-2 vaccination. A minority of patients attained seroconversion after booster vaccination. Strategies to improve immune response in these severely immunosuppressed patients are needed.
- 15 December 2021
- Published by Wiley in Vox Sanguinis
- Vol. 117 (4) , 553-561
Viscoelastometric versus standard coagulation tests to guide periprocedural transfusion in adults with cirrhosis: A meta‐analysis of randomized controlled trials
Background and Objectives Due to rebalanced haemostasis in cirrhosis, viscoelastometric testing (VET) is more accurate than standard coagulation tests (SCTs) in preprocedural haemostatic evaluation, resulting in decreased unnecessary transfusion. We aimed to determine the impact of VET-guided strategy on postprocedural bleeding, periprocedural transfusion rates and quantities, transfusion-related adverse events (TRAEs), lengths of stay (LOS) and mortality from randomized controlled trials (RCTs) of cirrhotic patients. Methods PubMed and EMBASE were searched for RCTs comparing VET-guided with SCT-guided transfusion in cirrhotic adults undergoing esophagogastroduodenoscopy, liver transplantation or other invasive interventions. Using random-effects models, the pooled risk ratios (RRs) and/or mean differences (MDs) of postprocedural bleeding-free events and the other outcomes were estimated alongside 95% confidence intervals (CIs). Results Of seven included RCTs (n = 421; 72.2% men; mean age 49.1 years), VET-guided transfusion did not change postprocedural bleeding-free statuses (RR 1.05; 95% CI 0.94–1.17). However, VET-based algorithms decreased the rates of fresh frozen plasma (FFP; RR 0.52; 95% CI 0.35–0.77) and platelet transfusions (RR 0.34; 95% CI 0.16–0.73), the quantities of transfused FFP (MD −1.39 units; 95% CI −2.18 to −0.60), platelets (MD −1.06 units; 95% CI −2.01 to −0.12) and cryoprecipitate (MD −7.13 units; 95% CI −14.20 to −0.07) and the risk of TRAEs (RR 0.42; 95% CI 0.27–0.65). The overall mortality rates and LOS were not significantly different between two groups. Conclusion Compared with conventional SCT-guided, VET-guided strategy decreases periprocedural plasma and platelet transfusions and TRAEs, without increasing haemorrhagic complications, LOS or mortality in cirrhosis.
- 15 December 2021
- Published by Wiley in Vox Sanguinis
- Vol. 117 (4) , 553-561
Viscoelastometric versus standard coagulation tests to guide periprocedural transfusion in adults with cirrhosis: A meta‐analysis of randomized controlled trials
Background and Objectives Due to rebalanced haemostasis in cirrhosis, viscoelastometric testing (VET) is more accurate than standard coagulation tests (SCTs) in preprocedural haemostatic evaluation, resulting in decreased unnecessary transfusion. We aimed to determine the impact of VET-guided strategy on postprocedural bleeding, periprocedural transfusion rates and quantities, transfusion-related adverse events (TRAEs), lengths of stay (LOS) and mortality from randomized controlled trials (RCTs) of cirrhotic patients. Methods PubMed and EMBASE were searched for RCTs comparing VET-guided with SCT-guided transfusion in cirrhotic adults undergoing esophagogastroduodenoscopy, liver transplantation or other invasive interventions. Using random-effects models, the pooled risk ratios (RRs) and/or mean differences (MDs) of postprocedural bleeding-free events and the other outcomes were estimated alongside 95% confidence intervals (CIs). Results Of seven included RCTs (n = 421; 72.2% men; mean age 49.1 years), VET-guided transfusion did not change postprocedural bleeding-free statuses (RR 1.05; 95% CI 0.94–1.17). However, VET-based algorithms decreased the rates of fresh frozen plasma (FFP; RR 0.52; 95% CI 0.35–0.77) and platelet transfusions (RR 0.34; 95% CI 0.16–0.73), the quantities of transfused FFP (MD −1.39 units; 95% CI −2.18 to −0.60), platelets (MD −1.06 units; 95% CI −2.01 to −0.12) and cryoprecipitate (MD −7.13 units; 95% CI −14.20 to −0.07) and the risk of TRAEs (RR 0.42; 95% CI 0.27–0.65). The overall mortality rates and LOS were not significantly different between two groups. Conclusion Compared with conventional SCT-guided, VET-guided strategy decreases periprocedural plasma and platelet transfusions and TRAEs, without increasing haemorrhagic complications, LOS or mortality in cirrhosis.